3.0
7. Dez. 2023
Ehemaliger Mitarbeiter, mehr als 5 Jahre
Minneapolis, MN
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Good benefits, good people, robust portfolio of science, ok work/life balance
Kontras
Upper management continues to make decisions that hamstring the science (ex. letting CRISPR license expire while developing gene editing technology, wants to expand into C> but lays off C> team), layoffs two years in a row in December, <50% trust in upper management in company survey, shareholders rejected the outrageous executive compensation plan so hard it ended up in the Star Tribune (Nov 1 2023)